ERBB2 and breast cancer: In sum, we showed that pharmacological inhibition of HSF1 simultaneously inhibits diverse adaptive responses endowing lapatinib resistance, as well as destabilizes potent oncogenic drivers of ERBB2-positive breast cancer, such as ERBB2, EGFR, and mutp53.